Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

about

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

Item

http://www.wikidata.org/entity/Q50625597

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@en

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@nl

type

Item

label

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@en

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@nl

prefLabel

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@en

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@nl

P1476

Exploiting Pharmacokinetic Mod ...... ons in Breast Cancer Patients.

@en

P2093

Charlotte Kloft

http://www.w3.org/2001/XMLSchema#string

Lena Klopp-Schulze

http://www.w3.org/2001/XMLSchema#string

Markus Joerger

http://www.w3.org/2001/XMLSchema#string

Rob Ter Heine

http://www.w3.org/2001/XMLSchema#string

Sebastian G Wicha

http://www.w3.org/2001/XMLSchema#string

P2860

Visualization and communication of pharmacometric models with berkeley madonna

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.

Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

Orally administered endoxifen is a new therapeutic agent for breast cancer.

Tamoxifen: a most unlikely pioneering medicine.

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

Effects of CYP induction by rifampicin on tamoxifen exposure.

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

P2888

s40262-017-0555-z

P304

229-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-017-0555-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chantal Csajka

Zinnia P Parra-Guillen

P577

2017-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28540639

http://www.w3.org/2001/XMLSchema#string